Suppr超能文献

载体基因组的快速脱壳是使用假型腺相关病毒载体进行高效肝脏转导的关键。

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

作者信息

Thomas Clare E, Storm Theresa A, Huang Zan, Kay Mark A

机构信息

Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305, USA.

出版信息

J Virol. 2004 Mar;78(6):3110-22. doi: 10.1128/jvi.78.6.3110-3122.2004.

Abstract

Transduction of the liver with single-stranded adeno-associated virus serotype 2 (AAV2) vectors is inefficient; less than 10% of hepatocytes are permissive for stable transduction, and transgene expression is characterized by a lag phase of up to 6 weeks. AAV2-based vector genomes packaged inside AAV6 or AAV8 capsids can transduce the liver with higher efficiency, but the molecular mechanisms underlying this phenomenon have not been determined. We now show that the primary barrier to transduction of the liver with vectors based on AAV2 capsids is uncoating of vector genomes in the nucleus. The majority of AAV2 genomes persist as encapsidated single-stranded molecules within the nucleus for as long as 6 weeks after vector administration. Double-stranded vector genomes packaged inside AAV2 capsids are at least 50-fold more active than single-stranded counterparts, but these vectors also exhibit a lag phase before maximal gene expression. Vector genomes packaged inside AAV6 or AAV8 capsids do not persist as encapsidated molecules and are more biologically active than vector genomes packaged inside AAV2 capsids. Our data suggest that the rate of uncoating of vector genomes determines the ability of complementary plus and minus single-stranded genomes to anneal together and convert to stable, biologically active double-stranded molecular forms.

摘要

用单链2型腺相关病毒(AAV2)载体转导肝脏的效率较低;不到10%的肝细胞允许稳定转导,且转基因表达的特征是存在长达6周的延迟期。包装在AAV6或AAV8衣壳内的基于AAV2的载体基因组能够更高效地转导肝脏,但这一现象背后的分子机制尚未明确。我们现在表明,基于AAV2衣壳的载体转导肝脏的主要障碍是载体基因组在细胞核内的脱壳。在载体给药后长达6周的时间里,大多数AAV2基因组以核内包裹的单链分子形式持续存在。包装在AAV2衣壳内的双链载体基因组的活性至少比单链对应物高50倍,但这些载体在达到最大基因表达之前也表现出延迟期。包装在AAV6或AAV8衣壳内的载体基因组不会以包裹分子的形式持续存在,并且比包装在AAV2衣壳内的载体基因组具有更高的生物活性。我们的数据表明,载体基因组的脱壳速率决定了互补的正链和负链单链基因组退火在一起并转化为稳定的、具有生物活性的双链分子形式的能力。

相似文献

3
Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid and genome conversion.
Transplantation. 2005 Sep 15;80(5):683-90. doi: 10.1097/01.tp.0000173381.97556.0d.
5
Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes.
J Virol. 2000 Feb;74(3):1524-32. doi: 10.1128/jvi.74.3.1524-1532.2000.
6
Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.
Mol Ther. 2007 Nov;15(11):1955-62. doi: 10.1038/sj.mt.6300293. Epub 2007 Aug 28.
7
Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
J Control Release. 2017 Sep 28;262:348-356. doi: 10.1016/j.jconrel.2017.08.005. Epub 2017 Aug 5.

引用本文的文献

1
Evaluation of AAV vectors with tissue-specific or ubiquitous promoters in a mouse model of mucopolysaccharidosis type IVA.
Mol Ther Methods Clin Dev. 2025 Mar 14;33(2):101447. doi: 10.1016/j.omtm.2025.101447. eCollection 2025 Jun 12.
2
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.
Mol Ther Methods Clin Dev. 2025 Jan 28;33(1):101424. doi: 10.1016/j.omtm.2025.101424. eCollection 2025 Mar 13.
3
Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry.
Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101293. doi: 10.1016/j.omtm.2024.101293. eCollection 2024 Sep 12.
4
Gene therapy and genome editing for type I glycogen storage diseases.
Front Mol Med. 2023 Mar 31;3:1167091. doi: 10.3389/fmmed.2023.1167091. eCollection 2023.
5
AAV Capsid Screening for Translational Pig Research Using a Mouse Xenograft Liver Model.
bioRxiv. 2024 May 29:2024.05.29.596409. doi: 10.1101/2024.05.29.596409.
7
Rationally engineered novel AAV capsids for intra-articular gene delivery.
Mol Ther Methods Clin Dev. 2024 Feb 14;32(1):101211. doi: 10.1016/j.omtm.2024.101211. eCollection 2024 Mar 14.
8
A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR.
Mol Ther Methods Clin Dev. 2024 Feb 3;32(1):101206. doi: 10.1016/j.omtm.2024.101206. eCollection 2024 Mar 14.
10
Biophysical characterization of adeno-associated virus capsid through the viral transduction life cycle.
J Genet Eng Biotechnol. 2023 May 17;21(1):62. doi: 10.1186/s43141-023-00518-5.

本文引用的文献

3
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
Blood. 2003 Oct 1;102(7):2412-9. doi: 10.1182/blood-2003-02-0495. Epub 2003 Jun 5.
4
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
Blood. 2003 Sep 15;102(6):2031-7. doi: 10.1182/blood-2003-01-0292. Epub 2003 May 8.
6
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2.
J Virol. 2002 Nov;76(22):11505-17. doi: 10.1128/jvi.76.22.11505-11517.2002.
8
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9. doi: 10.1073/pnas.182412299. Epub 2002 Aug 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验